Ranok Therapeutics
Latest round
- Series B
Last raised
- Aug 2021
Total raised
- $40M
Investors
- 6
About Ranok Therapeutics
Established in 2018 and based in Hangzhou, China, Ranok Therapeutics is a biotechnology company that engages in research and development of cancer treatment drugs. The company's founder and CEO, Weiwen Ying, formerly worked at Synta Pharmaceuticals and was the co-founder and president of Capten Therapeutics. He has more than 19 years of industry experience in medicinal chemistry, drug discovery, preclinical and clinical development. The company mainly develops chaperone-mediated Protein Degradation/Degrader (CHAMP) technology, which uses different underlying biological processes from other targeted protein degradation methods (such as PROTAC) and has many unique advantages, including the use of tumor tissue targets To improve the safety of drugs.
Who invested in Ranok Therapeutics
6 investors across 1 round
See all investors in Ranok Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series B
Aug 18, 2021
Amount
$40M
Investors
Questions about Ranok Therapeutics
Who invested in Ranok Therapeutics?
Ranok Therapeutics has 6 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Ranok Therapeutics raised?
Ranok Therapeutics has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Ranok Therapeutics last raise money?
Ranok Therapeutics's most recent round on record is a Series B, in Aug 2021.
What does Ranok Therapeutics do?
Established in 2018 and based in Hangzhou, China, Ranok Therapeutics is a biotechnology company that engages in research and development of cancer treatment drugs.
Where is Ranok Therapeutics headquartered?
Ranok Therapeutics is headquartered in Hangzhou, China.
Which VCs invest in companies like Ranok Therapeutics?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at Ranok Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Ranok Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.